We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Exploratory IND Sponsors Can Speed Development, FDA Says
Exploratory IND Sponsors Can Speed Development, FDA Says
April 15, 2005
Exploratory clinical trial sponsors involving drugs and therapeutic biological products have not been taking full advantage of the flexibility offered in terms of the amount of data that needs to be submitted with early exploratory investigational new drug (IND) applications, the FDA said.